Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System
January 31st, 2018
8.8K views
A novel technique for rapid antigen display on a bacterial surface is presented, which involves surface biotinylation followed by exposure to proteins of interest in fusion with monomeric avidin. Loading BCG with selected antigens successfully improves its immunogenicity, suggesting that surface decoration can replace traditional genetic approaches.
Overview
This article presents a novel technique for expressing surface proteins on mycobacterium through surface decoration with recombinant proteins. This method serves as an alternative to traditional genetic approaches, facilitating research in mycobacteriology and vaccine development.
Key Study Components
Area of Science
- Mycobacteriology
- Vaccine development
- Protein engineering
Background
- Traditional genetic approaches can be time-consuming.
- Surface decoration may enhance immunogenicity of BCG.
- Research in hospital interactions is critical.
- Screening for antigen candidates is essential for vaccine development.
Purpose of Study
- To improve the immunogenicity of BCG.
- To provide a rapid method for antigen display.
- To explore alternatives to genetic manipulation.
Methods Used
- Surface biotinylation of bacterial cells.
- Exposure to proteins of interest fused with monomeric avidin.
- Transformation of plasmids into E. coli BL21.
- Comparison of this method with traditional approaches.
Main Results
- Successful loading of BCG with selected antigens.
- Improved immunogenicity observed with surface decoration.
- Rapid comparison to traditional methods demonstrated.
- Potential for screening interference factors identified.
Conclusions
- Surface decoration can effectively replace genetic approaches.
- This technique offers a promising avenue for vaccine research.
- Further studies are needed to explore its full potential.
Frequently Asked Questions
What is the main advantage of this technique?
It provides a rapid alternative to traditional genetic methods for antigen display.
Who demonstrated the procedure?
Amina Talal, a research assistant, demonstrated the procedure.
What is the significance of improving BCG immunogenicity?
Improving BCG immunogenicity can enhance vaccine efficacy against tuberculosis.
How does surface decoration work?
It involves biotinylation followed by exposure to proteins fused with avidin.
What are potential applications of this method?
It can be used for screening antigen candidates and studying hospital interactions.
Is this method faster than traditional approaches?
Yes, it is designed to be faster and less time-consuming.
Executive Industry Relevance
This non-genetic surface decoration method offers a rapid, stable alternative to plasmid-based antigen expression in BCG vaccine development, addressing key limitations of low transformation efficiency and vector stability. By enabling exogenous antigen display without genetic manipulation, the approach supports faster screening of immunogenic candidates and reduces mechanistic uncertainty in early vaccine design. The demonstrated stability of surface-bound antigens after lyophilization suggests compatibility with scalable vaccine production workflows.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables functional validation of exogenous antigens on a clinically relevant bacterial surface without genetic modification.
- Operational Value: Provides a rapid screening platform for antigen candidates using standard E. coli expression and biotinylation workflows.
- Predictive Value: Supports assessment of antigen processing and presentation pathways through observed cytosolic translocation and MHC co-localization.
Screening & Assay Development
- Scientific Value: Generates quantifiable, stable antigen display on BCG measurable via flow cytometry and fluorescence microscopy.
- Operational Value: Uses standardized biotin-avidin chemistry compatible with high-throughput protein purification and labeling pipelines.
- Assay Readiness: Produces a reproducible vaccine surrogate for evaluating immune activation and antigen trafficking in macrophage models.
Translational & Preclinical Research
- Translational Value: Demonstrates antigen detachment and co-localization with MHC class I and II molecules, supporting potential for both CD4+ and CD8+ T-cell responses.
- Preclinical Model: Uses murine macrophage and phagocytosis assays to validate antigen processing and intracellular trafficking relevant to human immunity.
- Risk De-risking: Shows no adverse macrophage phenotype alteration, supporting safety evaluation of decorated BCG as a vaccine vector.
Pipeline & Workflow Integration
The method fits within the early discovery to preclinical transition, enabling rapid antigen screening prior to genetic engineering investment and supporting go/no-go decisions based on immunogenicity and antigen presentation data.
- Discovery Biology: Facilitates hypothesis testing of antigen immunogenicity and MHC presentation potential without genome modification.
- Screening: Generates standardized, quantifiable antigen display levels for comparing candidate proteins across expression batches.
- Analytics: Employs flow cytometry and microscopy to measure biotinylation efficiency, antigen binding stability, and intracellular antigen trafficking.
- Translational Research: Links surface decoration to antigen presentation compartments, supporting evaluation of vaccine-induced T-cell priming potential.
- Enterprise Reuse: Establishes a modular platform where diverse avidin-fused antigens can be applied to biotinylated BCG, enabling reuse across multiple target validation campaigns.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in antigen presentation by demonstrating cytosolic translocation and MHC loading potential.
- Operational Value: Employs biotin-avidin binding, a high-affinity, reversible system compatible with existing protein purification and labeling infrastructures.
- Strategic Value: Accelerates antigen evaluation timelines by bypassing cloning, transformation, and expression optimization steps.
- Portfolio Impact: Enables rapid prioritization of antigens based on surface display stability and immune response induction in preclinical models.
Implementation Considerations
- Requires expertise in protein expression, inclusion body refolding, and biotinylation chemistry.
- Depends on access to nickel NTA chromatography, flow cytometry, and fluorescence microscopy for validation.
- Necessitates biosafety level 2 practices for handling BCG and recombinant proteins.
- Involves optimization of biotinylation efficiency and avidin-fusion protein concentration for consistent surface decoration.
- Limited to antigens compatible with avidin fusion and bacterial surface display without disrupting BCG viability.
Biopharma FAQs
Why does biotinylation efficiency matter for antigen display on BCG?
Biotinylation efficiency determines the number of available binding sites for avidin-fused antigens, directly influencing the density and stability of surface decoration as measured by flow cytometry and fluorescence staining.
How does isolating the avidin-fusion protein variable enable antigen screening?
By expressing antigens as avidin fusions in E. coli, the variable of interest is the antigen itself, allowing standardized comparison of different proteins using the same biotinylated BCG scaffold and binding conditions.
What quantitative measurements enable assessment of antigen presentation potential?
Co-localization of detached avidin-OVA with MHC class I and II molecules, measured via fluorescence microscopy and immuno-gold staining, provides quantitative insight into antigen processing and loading onto antigen presentation pathways.
Why are replication requirements important for cross-functional validation of surface decoration?
Replication across batches confirms that biotinylation, protein binding, and antigen stability are consistent and not dependent on operator-specific technique, supporting reliable data transfer between discovery and preclinical teams.
What statistical analysis is required to compare antigen binding between biotinylated and non-biotinylated BCG?
Flow cytometry data showing minimal OVA binding to non-biotinylated controls versus significant binding to biotinylated BCG enables statistical comparison of specific versus non-specific antigen decoration, validating the method’s specificity.
Chapters in this video
0:05
Title
1:00
Monomeric Avidin Fusion Protein Expression, Purification, and Refolding
3:53
Biotinylation of BCG Cell Surface
5:47
Binding of Monomeric Adivin-fusion Protein to Biotinylated BCG Surface
7:06
Results: Biotinylation with Avidin-OVA
9:13
Conclusion
